23Sep 2024
Cytoreductive Nephrectomy Rates Declined After CARMENA Trial in the USA

Cytoreductive Nephrectomy Rates Declined After CARMENA Trial in the USA

The study analyzed the impact of the 2018 CARMENA trial on cytoreductive nephrectomy practices in the USA using data from the National Cancer Database (2004-2020). Results showed a statistically significant 31.8% relative reduction in CN rates among metastatic clear cell renal cell carcinoma patients post-2018, with actual rates dropping from 34.7% to 21.9%. The change suggests a broad shift in clinical practice following the CARMENA trial, though additional untested factors may have contributed. The study underscores how pivotal trials can influence treatment decisions nationwide.

  • #urology
  • #nephrology

Like

Save

Share